Jupiter Neurosciences starts enrollment in Parkinson’s Phase 2a RESET trial

By AI, Created 5:51 PM UTC, May 27, 2026, /AGP/ – Jupiter Neurosciences says patient enrollment is underway for its Phase 2a RESET trial of JOTROL™ in Parkinson’s disease, with first dosing expected soon. The study marks a key milestone for the company as it tests an investigational candidate in a market with no approved disease-modifying therapies.

Why it matters: - Parkinson’s disease has no approved disease-modifying therapies, leaving a major treatment gap. - Jupiter Neurosciences is testing JOTROL™, an investigational oral trans-resveratrol micellar formulation, in a Phase 2a study designed to evaluate whether it can address underlying drivers of neurodegeneration. - The company is targeting a large market with high unmet need, including an estimated 1.1 million people in the U.S. living with Parkinson’s disease and about 90,000 new U.S. diagnoses each year.

What happened: - Jupiter Neurosciences said patient enrollment is underway in the Phase 2a RESET clinical trial for Parkinson’s disease. - First patient dosing is expected in the near term. - The trial, listed as NCT07592767, is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study. - The study is being conducted at Georgetown University MedStar Hospital in Washington, D.C., Montgomery and Franklin Square Hospitals in Maryland, and MedStar McLean Clinic in Virginia.

The details: - JOTROL™ is an investigational drug candidate and has not been approved by the FDA or any other regulatory authority. - The Phase 1 study in 24 healthy volunteers showed no serious adverse events. - Phase 1 data also showed measurable cerebrospinal fluid drug levels, supporting central nervous system exposure. - Jupiter reported about 9-fold higher overall plasma bioavailability versus conventional resveratrol, with Cmax of 455 ng/mL versus 85 ng/mL in Phase 1. - The company said those data supported the IND cleared by the FDA in November 2025. - The Parkinson’s disease market was valued at $5.65 billion in 2024 and is projected to reach $7.58 billion by 2030, growing at a CAGR of about 5.04%. - Jupiter cited an annual U.S. economic burden of $82.2 billion tied to Parkinson’s disease. - The company also said roughly 90% of Parkinson’s disease patients are enrolled in Medicare. - Jupiter is a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation. - The company’s lead program is JOTROL™, and Jupiter also commercializes Nugevia™, a consumer longevity supplement. - Jupiter said it has entered into a term sheet to acquire ALA-002 from PharmAla Biotech, a next-generation patented psychedelic NCE. - The company said closing that transaction would expand its CNS pipeline, subject to due diligence, definitive agreements, regulatory approvals and other closing conditions. - More information is available in the company’s announcement, the Phase 1 clinical trial record, the journal article on CNS bioavailability, Parkinson’s disease statistics, CMS enrollment data, the FDA drug database, the market report source, the prevalence study, and Jupiter Neurosciences’ website.

Between the lines: - The Phase 2a study is a meaningful step, but it is still early clinical testing and does not establish efficacy. - The company is positioning JOTROL™ around central nervous system exposure and a preclinical neuroprotective signal, which are relevant but not yet proof of clinical benefit in Parkinson’s disease. - The broader market backdrop helps explain the company’s emphasis on timing, since disease-modifying options remain unavailable and development activity across the field is ongoing.

What’s next: - Jupiter expects first dosing in the RESET trial soon. - The company said it will generate clinical data as the trial progresses. - Investors will be watching for early safety, tolerability and signal-of-activity readouts from the Phase 2a study. - Jupiter said its proposed ALA-002 transaction remains dependent on customary closing conditions.

The bottom line: - Jupiter Neurosciences has crossed an important operational milestone, but the key test now is whether RESET can produce data that support JOTROL™ as a potential Parkinson’s disease therapy.